Vigabatrin (All indications) updated on 04-22-2025

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9805
R35090		 Kilic (Vigabatrin) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Preterm (< 37 weeks) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 0.38 [0.02;6.50] C
excluded (control group) 		0/13   83/880 83 13
ref
S9806
R35093		 Kilic (Vigabatrin) (Controls unexposed NOS) (Mixed indications), 2014 Preterm (< 37 weeks) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: No 0.76 [0.04;12.78] C
excluded (control group) 		0/13   33,974/676,834 33,974 13
ref
S9807
R35096		 Kilic (Vigabatrin) (Controls unexposed, sick) (Mixed indications), 2014 Preterm (< 37 weeks) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 0.51 [0.03;8.67] C 0/13   383/5,296 383 13
ref
Total 1 studies 0.51 [0.03;8.67] 383 13
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kilic (Vigabatrin) (Controls unexposed, sick) (Mixed indications), 2014Kilic, 2014 1 0.51[0.03; 8.67]383130%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Vigabatrin) (Controls unexposed, sick) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.51[0.03; 8.67]38313 -NAKilic (Vigabatrin) (Controls unexposed, sick) (Mixed indications), 2014 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.51[0.03; 8.67]38313 -NAKilic (Vigabatrin) (Controls unexposed, sick) (Mixed indications), 2014 1 Tags Adjustment   - No  - No 0.51[0.03; 8.67]38313 -NAKilic (Vigabatrin) (Controls unexposed, sick) (Mixed indications), 2014 1 Controls   - epilepsy indication  - epilepsy indication 0.51[0.03; 8.67]38313 -NAKilic (Vigabatrin) (Controls unexposed, sick) (Mixed indications), 2014 1 All studiesAll studies 0.51[0.03; 8.67]38313 -NAKilic (Vigabatrin) (Controls unexposed, sick) (Mixed indications), 2014 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9805, 9806

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.76[0.04; 12.78]33,97413 -NAKilic (Vigabatrin) (Controls unexposed NOS) (Mixed indications), 2014 1 unexposed, sick controlsunexposed, sick controls 0.51[0.03; 8.67]38313 -NAKilic (Vigabatrin) (Controls unexposed, sick) (Mixed indications), 2014 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.38[0.02; 6.50]8313 -NAKilic (Vigabatrin) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 10.510.01.0